Cardiff Oncology, Inc. - Common Stock (CRDF)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRDF on Nasdaq
Shares outstanding
66,577,393
Price per share
$2.81
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
25,150,264
Holdings value
$51,811,088
% of all portfolios
0%
Share change
-3,461,907
Value change
-$9,699,936
Average buys %
+0%
Average sells %
-0%
Number of holders
109
Price from insider filings
$2.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cardiff Oncology, Inc. - Common Stock (CRDF) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 5.8% +38% $10,678,250 +$2,780,523 3,841,097 +35% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.6% $11,744,252 3,728,334 The Vanguard Group 30 Jun 2025
PFIZER INC 3.6% $6,704,178 2,411,575 Pfizer Inc. 13-5315170 31 Dec 2024
As of 30 Sep 2025, Cardiff Oncology, Inc. - Common Stock (CRDF) has 109 institutional shareholders filing 13F forms. They hold 25,150,264 shares of 66,577,393 outstanding shares (38%) .

Top 25 institutional shareholders own 35% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6% 3,985,536 +1.2% 0% $8,210,204
VANGUARD GROUP INC 5.4% 3,588,933 -3.7% 0% $7,393,202
Laurion Capital Management LP 3.7% 2,465,872 +37% 0.69% $5,079,696
Pfizer Inc 3.6% 2,411,575 0% 1.1% $4,967,845
BLAIR WILLIAM & CO/IL 3.3% 2,213,606 -12% 0.01% $4,560,028
ACORN CAPITAL ADVISORS, LLC 2.9% 1,962,084 +39% 2.1% $4,041,893
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,543,320 +3% 0% $3,180,068
STATE STREET CORP 1.7% 1,146,359 +1.8% 0% $2,361,500
FLPUTNAM INVESTMENT MANAGEMENT CO 0.9% 597,233 +1009% 0.02% $1,230,300
NORTHERN TRUST CORP 0.78% 519,752 -28% 0% $1,070,690
GOLDMAN SACHS GROUP INC 0.68% 454,726 +496% 0% $936,736
Bank of New York Mellon Corp 0.52% 347,485 +4.1% 0% $715,819
MORGAN STANLEY 0.47% 310,659 -61% 0% $639,958
NATIONAL BANK OF CANADA /FI/ 0.31% 208,700 +652088% 0% $429,922
UBS Group AG 0.31% 206,175 +4.4% 0% $424,721
TWO SIGMA INVESTMENTS, LP 0.31% 204,010 -54% 0% $420,261
Nuveen, LLC 0.29% 194,310 -65% 0% $400,279
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.28% 189,315 0% 0% $389,989
JANE STREET GROUP, LLC 0.24% 161,928 0% $333,572
XTX Topco Ltd 0.23% 156,161 +20% 0.02% $321,692
Avestar Capital, LLC 0.21% 140,469 0% 0.02% $289,366
ROYAL BANK OF CANADA 0.17% 116,405 -39% 0% $241,000
AlphaCore Capital LLC 0.17% 109,926 +8.2% 0.01% $226,448
RENAISSANCE TECHNOLOGIES LLC 0.15% 101,800 -22% 0% $209,708
Cubist Systematic Strategies, LLC 0.13% 88,903 0% $183,140

Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 23,249 $65,329 +$1,998 $2.81 2
2025 Q3 25,150,264 $51,811,088 -$9,699,936 $2.06 109
2025 Q2 28,660,334 $90,269,224 -$11,262,615 $3.15 114
2025 Q1 32,345,011 $101,559,895 +$10,196,300 $3.14 116
2024 Q4 28,092,578 $121,918,732 +$50,159,924 $4.34 117
2024 Q3 12,761,449 $34,074,638 -$895,795 $2.67 82
2024 Q2 13,089,737 $29,054,064 +$5,567,075 $2.22 90
2024 Q1 8,576,486 $45,797,587 +$17,940,647 $5.34 74
2023 Q4 5,309,425 $7,858,363 -$215,046 $1.48 55
2023 Q3 5,456,265 $7,583,910 -$756,925 $1.39 55
2023 Q2 5,991,988 $8,808,700 -$1,673,969 $1.47 50
2023 Q1 7,049,719 $11,633,255 -$748,502 $1.65 52
2022 Q4 7,699,341 $10,776,288 -$189,952 $1.40 55
2022 Q3 7,924,242 $12,205,032 -$1,956,121 $1.54 47
2022 Q2 8,925,020 $19,636,792 -$17,827,128 $2.20 54
2022 Q1 16,524,301 $40,953,207 -$30,166,620 $2.48 81
2021 Q4 22,015,576 $132,083,136 +$5,192,808 $6.01 81
2021 Q3 21,121,086 $140,722,888 -$35,953,961 $6.66 82
2021 Q2 26,525,986 $176,397,333 +$10,825,969 $6.65 81
2021 Q1 24,079,194 $222,960,463 -$69,848,932 $9.26 70
2020 Q4 26,636,620 $479,141,900 +$144,188,615 $17.99 79
2020 Q3 18,710,542 $265,500,071 +$207,902,213 $14.19 63
2020 Q2 4,923,525 $24,668,025 +$24,668,026 $5.01 23